Last reviewed · How we verify
RV3-BB
At a glance
| Generic name | RV3-BB |
|---|---|
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine (PHASE2)
- Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RV3-BB CI brief — competitive landscape report
- RV3-BB updates RSS · CI watch RSS
- PATH portfolio CI